SMARCB1 and epithelioid sarcoma: This study confirmed that reintroducing INI1 in epithelioid sarcoma (EpS) markedly reduced cell proliferation, eradicated tumorigenicity, and downregulated AURKA and its downstream effectors, including PLK1 and CDC25C.